These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 12719028)

  • 1. The pharmacokinetics of s.c. Semitard MC, human NPH ge, Rapitard MC and human NPH 30:70 ge insulin in healthy, non-diabetic subjects.
    Luzio SD; George L; Beck P; Chester P; Owens DR
    Eur J Intern Med; 2003 Mar; 14(2):107-112. PubMed ID: 12719028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the activity of Rapitard and Actraphane insulins.
    Colagiuri S; Jones S
    Diabete Metab; 1988 Dec; 14(6):689-92. PubMed ID: 3073090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
    Owens DR; Coates PA; Luzio SD; Tinbergen JP; Kurzhals R
    Diabetes Care; 2000 Jun; 23(6):813-9. PubMed ID: 10841002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.
    Koivisto VA; Tuominen JA; Ebeling P
    Diabetes Care; 1999 Mar; 22(3):459-62. PubMed ID: 10097929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique.
    Bottermann P; Gyaram H; Wahl K; Ermler R; Lebender A
    Diabetes Care; 1982; 5 Suppl 2():43-52. PubMed ID: 6765540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characterisation of activity of a biphasic monocomponent insulin (author's transl)].
    Neubauer M; Althoff PH; Schnabel O; Genrich V; Schöffling K
    Dtsch Med Wochenschr; 1979 Mar; 104(11):384-90. PubMed ID: 421667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of five pre-mixed combinations of 'short-' and 'intermediate-acting' (NPH) insulins in healthy subjects following subcutaneous administration.
    Owens DR; Jones AL; Dolben J; Dean JD; Petocz P; Coates PA; Luzio SD
    Diabetes Res; 1993; 22(2):77-86. PubMed ID: 8205740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
    Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M
    Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics and metabolic activity of biosynthetic NPH insulin evaluated by the glucose clamp technique.
    Massi Benedetti M; Bueti A; Mannino D; Bellomo G; Antonella MA; Calabrese G; Zega G; Brunetti P
    Diabetes Care; 1984; 7(2):132-6. PubMed ID: 6376009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients.
    HOE 901/2004 Study Investigators Group
    Diabet Med; 2003 Jul; 20(7):545-51. PubMed ID: 12823235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
    Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
    Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
    Luzio SD; Beck P; Owens DR
    Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects.
    Bantle JP; Neal L; Frankamp LM
    Diabetes Care; 1993 Dec; 16(12):1592-7. PubMed ID: 8299455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.